The markedly prolonged survival of the IPI-504-treated BCR-ABL-T315I-induced CML mice correlates with the more pronounced in vivo degradation of the mutant BCR-ABL than that of wild type BCR-ABL. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.